



**Office of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**September 9, 2008 6:30 – 9:00 p.m.**

- 1. Executive Session** **6:30 - 7:00**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**  
(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:25**
  - Clinical Programs Update
  - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:25 - 7:35**
  - Suboxone<sup>®</sup>/Subutex<sup>®</sup>
  - Asthma – overuse of SABA
- 6. Clinical Update: Drug Reviews** **7:35 – 8:15**  
(Public comment prior to Board action)
  - Bystolic<sup>®</sup> (nebivolol)
  - Luvox<sup>®</sup> CR (fluvoxamine)
  - Pristiq<sup>®</sup> (desvenlafaxine SR)
  - Treximet<sup>®</sup> (sumatriptan/naproxen)
  - Veregan<sup>®</sup> (sinecatechins) Ointment**New Dosage Forms**
  - Lamisil<sup>®</sup> Granules (terbinafine)
  - Emend<sup>®</sup> Injection
  - Protonix<sup>®</sup> Pak
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **8:15 – 8:25**  
(Public comment prior to Board action)
  - Antidepressants – rename/restructure of class “Novel”
  - Cymbalta<sup>®</sup> (fibromyalgia)
  - Lyrica<sup>®</sup> (differentiation of diagnoses)
- 8. Drug Classes – New** **8:25 – 8:25**
  - No new drug classes

<b>9. RetroDUR</b>	<b>8:25 - 8:35</b>
▪ Compounded Products (including topical analgesics)	
<b>10. New Drug Product Plan Exclusions (Consent Agenda Topic)</b>	<b>8:35 - 8:40</b>
<b>11. Updated New-to-Market Drug Monitoring Log</b>	<b>8:40 - 8:45</b>
<b>12. General Announcements</b>	<b>8:45 - 9:00</b>
<b>Selected FDA Safety Alerts</b>	
▪ Vytorin <sup>®</sup> – possible increased cancer incidence	
▪ Tysabri <sup>®</sup> – two new cases of PML	
<b>13. Adjourn</b>	<b>9:00</b>